The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after announcing a merger with ITM Isotope Technologies Munich SE, a global leader in therapeutic radioisotopes. The deal could create a radiopharmaceutical powerhouse, with combined estimated 2026 revenue over US$1.3 billion and deeper supply chain security for Telix’s growing pipeline.
What did Telix Pharmaceuticals report?
- Strategic agreement to acquire 100% of ITM for US$1.65 billion upfront (cash-free/debt-free)
- Post-adjustments, ~US$1.25 billion in Telix shares to ITM shareholders, plus up to US$700 million in milestone payments
- Pro forma combined revenue projected at over US$1.3 billion for 2026
- ITM achieved US$273 million revenue in 2025, with a 40% CAGR from 2021â2025
- Combined group expected to generate positive EBITDA from 2027 onwards
What else do investors need to know?
The merger positions Telix as a vertically integrated leader, with capabilities across radioisotope production, global manufacturing, and therapeutic development. ITM brings expertise in commercial-scale isotope production, including lutetium-177, actinium-225, and terbium-161, and serves over 65 countries.
ITM’s late-stage pipeline includes ITM-11, a novel candidate for treating neuroendocrine tumours, which has completed a Phase 3 trial. This potentially accelerates Telix’s entry into established commercial markets and complements its existing precision medicine platform.
The transaction is subject to shareholder and regulatory approval, with closing expected by the end of FY2026. Following completion, Telix shareholders will own about 76.3% of the combined group, and ITM shareholders the remaining 23.7%.
What did Telix Pharmaceuticals management say?
Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said:
This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector. Importantly, this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security, while bringing together the mission-critical capabilities needed to deliver radiopharmaceutical treatments to patients around the world.
What’s next for Telix Pharmaceuticals?
Telix expects the merger to drive new growth opportunities, deepen its global supply chain, and enhance its ability to deliver innovative cancer therapies. The launch of ITM-11, if approved, could open up additional high-margin revenues in targeted radionuclide therapy markets.
Management anticipates further cost savings, manufacturing efficiencies, and synergy benefits post-merger. An extraordinary general meeting is planned for November 2026 to seek shareholder approval.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have risen 19%, outpacing the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.
The post Telix Pharmaceuticals: ITM merger builds a sector leader appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- These are the 10 most shorted ASX shares
- ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
- Forget CSL shares, I’d buy this ASX biotech stock instead
- 4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown
- Are Telix shares a buy after its big US FDA news?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.